Multi-registry Analysis of Patients with Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) to Improve Capture of Demographic Data and Compare Visual Outcomes (P2-9.006)

Abstract

<h3>Objective:</h3> To combine American Academy of Neurology Axon Registry® data and American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) data to reduce missingness of demographic information and characterize visual outcomes in patients with MS and NMO. <h3>Background:</h3> The Axon Registry provides real-world data for patients with MS and NMO. However, some data are incomplete (e.g. demographics) and some relevant outcomes are not systematically captured in neurology documentation (e.g. visual acuity [VA]). The IRIS Registry contains demographic and visual function data that may complement Axon Registry-derived data to enhance understanding of real-world outcomes. <h3>Design/Methods:</h3> In this cross-sectional study, participants were included if they had repeated ICD-9/10 codes for MS or NMO in the Axon Registry and overlapped temporally in both registries. Age, sex, race, ethnicity and US census region were extracted and classified as conflicting, missing, and not missing in the combined data set. The IRIS Registry contributed VA data. <h3>Results:</h3> Among 60,316 patients with MS and 1,068 patients with NMO in the Axon Registry, 14,085 and 252 had temporal overlap in the IRIS Registry. When we combined data for the MS cohort, there was a 9–18% absolute reduction in missing or conflicting data for race, ethnicity, and location (all p=&lt;0.0005, McNemar), but not age (p=1.0, McNemar) or sex (p=0.08, McNemar). For patients in both registries, 10,907 with MS and 142 with NMO had VA data. VA was worse in patients with NMO (0.17 logMAR, 95%CI 0.12,0.21, p&lt;0.0005, linear model with age, gender). <h3>Conclusions:</h3> Using data from two registries reduced missing data for race, ethnicity and location and enabled examination of outcomes captured in the IRIS Registry for conditions that are diagnosed more frequently in the Axon Registry, demonstrating the utility of a multi-registry analysis. <b>Disclosure:</b> Dr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Twenty Twenty Therapeutics. Dr. Moss has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Verana Health. Dr. Moss has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink Inc. Dr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Firms. The institution of Dr. Moss has received research support from NIH. The institution of Dr. Moss has received research support from Department of Defense. The institution of Dr. Moss has received research support from Research to Prevent Blindness. Dr. Moss has received personal compensation in the range of $0-$499 for serving as a grant review panel with NASA. Dr. Moss has received personal compensation in the range of $0-$499 for serving as a grant review panel with National Institutes of Health. Dr. Moss has a non-compensated relationship as a Board of Directors with North American Neuro-ophthalmology Society that is relevant to AAN interests or activities. Lauren Wiener has received personal compensation for serving as an employee of Verana Health. Ms. Rizy has received personal compensation for serving as an employee of Verana Health. Ms. Rizy has stock in Verana Health. Dr. Baxi has received personal compensation for serving as an employee of Verana health . Dr. Kocher has received personal compensation for serving as an employee of Verana Health. Dr. Torres has received personal compensation for serving as an employee of Verana Health. Dr. Mbagwu has received personal compensation for serving as an employee of Verana Health. Dr. Mbagwu has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Verana Health. Dr. Mbagwu has received research support from Stanford University. Dr. Mbagwu has received intellectual property interests from a discovery or technology relating to health care.